Given the unprecedented predictive value of PD-L1 and CTLA-4 expression in immunotherapy, investigating the different regulators of PD-L1 and CTLA-4 expression that may influence immunotherapeutic efficacy will contribute to the individualized clinical management of cancer patients [19, 20]. The gene discussed is CD274; the disease is cancer.